Budget impact model of tovecimig: model outcomes
No evidence found.
Outcomes reported by economic evaluations in advanced biliary tract cancer
“For cost-effectiveness and cost–utility studies, we extracted ICERs, QALYs, life-years, total and incremental costs, willingness-to-pay thresholds, and the probability of cost-effectiveness where available.” (opens the source at this quote in a new tab)
“For cost-of-illness and resource-use studies, we extracted mean or median costs, cost categories, healthcare utilization, hospitalizations, treatment-line costs, productivity outcomes where reported, and principal cost drivers.” (opens the source at this quote in a new tab)